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ABSTRACT
Background: Currently mainly BRAF mutant circulating tumor DNA (ctDNA) is
utilized to monitor patients with melanoma. TERT promoter mutations are common in
various cancers and found in up to 70% of melanomas, including half of BRAF wildtype cases. Therefore, a sensitive method for detection of TERT promoter mutations
would increase the number of patients that could be monitored through ctDNA
analysis.
Methods: A droplet digital PCR (ddPCR) assay was designed for the concurrent
detection of chr5:1,295,228 C>T and chr5:1,295,250 C>T TERT promoter mutations.
The assay was validated using 39 melanoma cell lines and 22 matched plasma and
tumor samples. In addition, plasma samples from 56 metastatic melanoma patients
and 56 healthy controls were tested for TERT promoter mutations.
Results: The established ddPCR assay detected TERT promoter mutations with
a lower limit of detection (LOD) of 0.17%. Total concordance was demonstrated
between ddPCR and Sanger sequencing in all cell lines except one, which carried
a second mutation within the probe binding-site. Concordance between matched
plasma and tumor tissue was 68% (15/22), with a sensitivity of 53% (95% CI, 27%79%) and a specificity of 100% (95% CI, 59%-100%). A significantly longer PFS
(p=0.028) was evident in ctDNA negative patients. Importantly, our TERT promoter
mutations ddPCR assay allowed detection of ctDNA in 11 BRAF wild-type cases.
Conclusions: The TERT promoter mutation ddPCR assay offers a sensitive test for
molecular analysis of melanoma tumors and ctDNA, with the potential to be applied
to other cancers.
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INTRODUCTION

ddPCR [18, 23, 25-27]. In particular, our laboratory has
demonstrated that ctDNA analysis allows tracking of
patient response to therapy and resistance acquisition
[23]. Given the high prevalence of the TERT promoter
mutations C228T and C250T in cutaneous melanoma
[5, 28], their addition to existing tests for detection of
mutant BRAF and NRAS will allow monitoring of most
melanoma patients using ddPCR. Furthermore, it has
been shown that concurrence of mutations in the TERT
promoter with BRAF or NRAS mutations predispose
patients to fast growing and aggressive disease, thus
detection of multiple mutations including mutant TERT
could serve as a prognostic marker.
We report here on the development of a ddPCR
probe based assay to simultaneously detect the TERT
promoter mutations C250T and C228T. One probe binds
the wild-type sequence overlapping position C228, while
a second probe binds the mutant sequence resulting from
C228T or C250T mutations, as both mutations reconstitute
the putative ETS binding site (Figure 1). First, we tested
the concordance of this assay for the detection of TERT
promoter mutations in 39 melanoma cell lines relative
to Sanger sequencing, and in 22 plasma samples relative
to patient matched tumor tissue. We also determined the
sensitivity and specificity of this assay for the detection of
TERT promoter mutations using plasma derived cfDNA
from 56 melanoma patients and 56 healthy controls.

Telomerase reverse transcriptase (TERT) encodes
the catalytic subunit of telomerase, a ribonucleoprotein
responsible for maintaining telomere length of chromosomes
which play an integral role in cell immortality. Using
linkage analysis and high-throughput sequencing, Horn
et al. [1] reported somatic mutations in 74% of metastatic
melanoma human cell lines, 85% of metastatic melanoma
tumor tissues and 33% of primary melanomas. These
mutations are the result of a cytidine to thymidine transition
in the promoter of the TERT gene, at chromosome 5,
1,295,228 C>T and 1,295,250 C>T, hereafter termed C228T
and C250T. These mutations create a putative consensus
ETS (E26 transformation-specific) /ternary complex
factor binding motif (GGAA/T), which is associated with
an increase in TERT expression [1, 2]. The presence of
these mutations in cutaneous melanoma is associated with
fast growing melanomas [3] and poor prognosis [4]. The
co-existence of TERT promoter mutations with BRAF or
NRAS mutations (in 55% of cases) is associated with poor
disease-free and melanoma-specific survival [5]. TERT
promoter mutations occur frequently in a number of other
cancers: 80–90% of glioblastoma multiforme, 60% of
hepatocellular carcinoma, 60% of bladder cancer, 70%
of basal cell carcinoma, 50% of cutaneous squamous cell
carcinoma and up to 30% of thyroid cancers [6-11] and are
associated with aggressive disease in thyroid carcinoma
[12], glioblastoma [13], neuroblastoma [14] and renal cell
carcinoma [15]. Therefore, it is of significant clinical benefit
to develop a non-invasive and sensitive test that determines
the TERT promoter mutation status in cancer patients.
Molecular profiling of tumors to aid cancer
prognosis and to identify actionable therapeutic targets has
become routine practice in clinical oncology. Whilst tumor
tissue samples are typically used for mutation analysis,
access to the tumor for biopsy, and the quality and quantity
of the sample may hinder detection, particularly when
methods with limited sensitivity are employed. Commonly
used methods include Sanger sequencing, melting
curve analysis and pyrosequencing which have limits
of sensitivity of 15%-20%, 10% and 5% respectively
[16]. More recently, tumor related aberrations have been
determined in plasma cell free DNA (cfDNA) [17-22].
This is referred to as “liquid biopsy”, a relatively noninvasive test that can be performed regularly and provides
information from the sum of all tumors at any one time
point. It is, therefore, a valuable biomarker for monitoring
disease progression and response to therapy [19, 23].
Whilst a variety of methods have been used to detect
mutations from circulating tumor DNA (ctDNA), Hindson
et al., have shown droplet digital PCR (ddPCR) to be a
highly sensitive platform, enabling absolute quantitation
of mutant BRAF down to 0.001% allelic fraction [24].
Various studies have since shown the utility of testing
mutant BRAF in plasma of melanoma patients using
www.impactjournals.com/oncotarget

RESULTS
The designed primer sets were tested for amplification
of the genomic region of interest by end-point PCR.
Amplification conditions were optimized by testing a range
of annealing temperatures (55-61ºC). As shown in Figure
2A, the primers failed to amplify the required fragment in
the absence of Q-solution (Qiagen). Optimal amplification
was achieved in the presence of Q-solution between
61-64ºC (Figure 2B). The PCR fragment obtained was
subjected to Sanger sequencing to confirm its specificity.
Next, droplet digital PCRs were performed at a
gradient of annealing temperatures from 52°C to 65°C
for the detection of the C228T mutation in gDNA from
1205Lu cells (Figure 2C and 2D) and the C250T mutation
in gDNA from UACC62 cells (Figure 2E and 2F). Optimal
droplet segregation was observed at 57°C. Hereafter
all ddPCR assays were performed with an annealing/
extension temperature of 57°C.
To evaluate the quantitative linearity and the limit
of detection (LOD) of the ddPCR assay, serial dilutions of
mutant gDNA from cell lines 1205Lu (C228T mutant) and
UACC62 (C250T mutant) were mixed in a background
of wild-type human genomic DNA to achieve a final
concentration of gDNA of 20 ng/μL (Figure 3), with each
dilution tested in 8 replicates. At 0% mutant DNA, we
identified that a maximum of 2 false positive droplets were
observed in some of the 8 replicates, with an average of
78891
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0.068 ± 0.049%. Therefore, the lower LOD was defined
at 0.17%, the percentage false positives detectable at two
standard deviations over mean background [29].
To validate the assay, we tested 39 cell lines with
known TERT promoter mutant or wild-type status (Table
1). We confirmed detection of the C228T and/or the
C250T TERT promoter mutation in only those cell lines
identified as positive for these two mutations, while those
previously identified as wild-type showed no positivity for
TERT DNA mutations by ddPCR. Cell lines that harbored
an alternative TERT mutation other than C228T or C250T
showed as wild-type in our assay. In addition, the C250T
mutation was not detected in cell line C021, due to the
presence of a C253T single nucleotide polymorphism
in the probe binding site (Supplementary Figure 1).
Simultaneous C250T and C253T mutations have been
reported in 2% of melanoma cells lines [1].
Tumor tissue samples from 22 stage IV (AJCC)
metastatic melanoma patients were tested for C228T and
C250T TERT promoter mutations by ddPCR using the
TERT assay (Table 2). As reported in the literature [4, 28,
30], most tumor tissues tested harbored at least one of these
mutations (68%, n=15); 11 harbored the C228T mutation
and 4 harbored the C250T mutation. No tissue samples
were found to contain both TERT promoter mutations.
Plasma derived cfDNA from these 22 patients
were also tested for TERT promoter mutations. These
plasma samples were collected from patients with active
metastatic disease prior to any systemic therapeutic
intervention. Overall, the concordance rate between tumor
tissue and plasma testing was 68% (15/22). No patient
was positive for a TERT promoter mutation in plasma
and negative in its corresponding tumor tissue (100%
specificity). Of 15 plasmas from patients with confirmed
TERT promoter positive tumors, 8 were identified as
positive for the same mutation, whereas 7 cases were
positive in the tissue but negative in the plasma sample
(Table 2). Thus, the sensitivity of our TERT C228T/C250T

mutation detection in plasma was estimated as 53% (95%
CI 27%-79%). In a cox regression analysis, patients with
detectable ctDNA at baseline (n=8) had a significantly
shorter progression free survival (PFS) compared to
patients that had no detectable ctDNA (n=7) (p=0.028,
Hazard ratio: 4.48 (CI, 1.18-17.06) (Figure 4A).
To further demonstrate the detection rate of TERT
ctDNA in metastatic melanoma we tested 56 plasma
samples from randomly selected stage IV (AJCC)
melanoma patients (mean age 65 years, ranging from
35 to 85 years) with known BRAF but unknown TERT
mutational status and compared this to 56 plasma samples
from healthy individuals (mean age 51 years, ranging
from 24 to 81 years). The TERT ddPCR assay detected a
statistically significant difference in the copies of mutant
TERT ctDNA in plasma from metastatic melanoma
patients relative to those from healthy controls (p=0.006,
Figure 4). We found TERT mutant DNA in 11 of 38 BRAF
wild-type and in 4 of the 18 BRAF V600E/K patients.
The number of TERT promoter copies per mL of plasma
detected in the melanoma patient cohort varied from 11.2
to 176 copies per mL (Figure 4). No TERT promoter
mutant DNA was detected in any of the 56 healthy control
plasmas. Based on these results the assay specificity was
estimated as 100% (95% CI 94%-100%).

DISCUSSION
Here we describe and validate a method to detect
the two most common TERT promoter mutations found
in melanoma tumors using ddPCR. TERT promoter
mutations occur in melanoma as frequently as [4], or more
frequently [5] than BRAF mutations, and yet mainly BRAF
mutant specific cfDNA is being used to monitor melanoma
patients for response to therapy and disease progression
[26]. The inclusion of TERT promoter mutations within
ctDNA for monitoring would increase the number of
patients for whom ctDNA could be used to determine

Figure 1: Location of ddPCR assay probes relative to ETS1 binding motifs generated by the C228T and C250T TERT
promoter mutations. Probes for the identification of wild-type and mutant sequences are indicated. Both mutant sites are detected by
the same probe.
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disease status, particularly amongst BRAF and NRAS wildtype melanoma patients. This will enable large studies
on the clinical utility of ctDNA monitoring to provide
evidence of the efficacy of this marker for determining
disease progression, to inform cessation of ineffective
therapies [23, 27] and to guide alternative therapy.
Our assay allowed for detection of mutant TERT
in biologically relevant samples, such as FFPE tumor
DNA and plasma of metastatic melanoma patients at high
specificity. Using cell line derived DNA, we optimized
the assay to detect as little as 0.17% mutant TERT DNA
in dilutions of wild-type DNA. This is significantly
lower than limits of detection reported for other mutation
detection platforms such as allele specific PCR at 1% [31]
and pyrosequencing at 5%, melting curve analysis at 10%
and Sanger sequencing at 20% [16]. While we and others

have shown ddPCR to detect BRAF mutant fraction as
low as 0.001% [24, 32], we were unable to achieve this
sensitivity with the TERT assay developed here, possibly
due to the highly GC rich area of the promoter region
of this gene, resulting in background signal and limited
segregation of positive and negative droplets. In fact,
during the development of this assay, multiple primers,
probes and amplification conditions were tested without
success. The conditions detailed here, including the
addition of LNA at the specific nucleotides and the use of
Q-solution in the amplification mix, were indispensable
for successful amplification.
We validated the assay in terms of accuracy
and reliability by showing 97.4% concordance with
the genotype of 39 melanoma cell lines. Of the cell
lines analyzed that harbored either a C228T or C250T

Figure 2: Optimization of ddPCR for detection of TERT promoter mutations. PCR fragments from cell line 1205Lu amplified
at varying temperatures without (A) and with (B) “Q solution”. gDNA of cell lines 1205Lu-C228T (C and D) and UACC62-C250T (E and
F) were used as template for the TERT ddPCR at varying annealing temperatures. FAM signal from mutant probe binding to C228T (C) or
C250T (E). HEX signal from binding of wild-type probe (D and F).
www.impactjournals.com/oncotarget
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mutation, 14 were heterozygous and 9 homozygous.
A major limitation of our assay is that it cannot detect
other TERT promoter mutations and it can be affected by
SNPs within the probe binding sites. This was apparent
by the results obtained from 9 cell lines with known
TERT promoter dinucleotide mutations C227T/C228T
and C241T/C242T, which have been reported to exist
in 5.2% and 10.4% of primary melanomas respectively
[1]. Similarly, a negative result was reported for cell line
CO12 which harbors a C253T SNP on the probe binding
site. Further development of ddPCR assays to detect these
other TERT promoter mutations [5] would ensure that

a maximum number of patients could be monitored. In
addition and given that SNPs in this region can also affect
patient prognosis [5], germline sequence analysis should
be performed complementary to the analysis of TERT
promoter somatic mutations.
It is notable that all patients with TERT promoter
mutations in plasma had corresponding mutations in
matched tumor tissue and as such no false positive plasma
samples were detected. High concordance between
mutational profiles in plasma ctDNA and matched tumor
tissue have been reported in several studies from patients
with melanoma [18, 25, 26], breast cancer [20, 33, 34],

Figure 3: Detection of TERT promoter mutations in the presence of homologous wild-type DNA. Serial dilutions of DNA
from mutant cell lines 1205Lu – C228T (A-D) and UACC62 – C250T (E-H) were prepared in a constant background of wild-type human
genomic DNA. 2D plots of ddPCR read out at 10% of mutant DNA (A and E). 1D plots indicating mutant (B and F) and wild-type (C and G)
DNA detection. Analytical sensitivity (LOD) of the assay (D and H). Obtained frequency abundances and standard deviations were plotted
versus expected mutant frequencies based on input. The LOD, defined as 2 SD over the mean frequency abundance obtained at 0% when
only wild-type DNA was used as input, was indicated as dashed lines in both graphs.
www.impactjournals.com/oncotarget
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Table 1: Validation of C228T and C250T TERT promoter mutation detection in melanoma cell lines
Cell line

Sanger sequencing

ddPCR

C024

wt

wt

C055

wt

wt

C092

wt

wt

C096

wt

wt

HGA

wt

wt

C022

C228T

C228T

C037

C228T

C228T

C058

C228T

C228T

D41

C228T

C228T

MM409

C228T

C228T

D22

C228T

C228T

MM473

C228T

C228T

A06

a

C228T

C228Ta

C076

C228Ta

C228Ta

MM455

C228Ta

C228Ta

1205Lu

C228Ta

C228Ta

A15

C250T

C250T

A14

C250T

C250T

C002

C250T

C250T

MM537

C250T

C250T

SKMEL13

C250T

C250T

MM386

C250T

C250T

D01

C250T

C250T

MM229

a

C250T

C250Ta

MM253

C250Ta

C250Ta

MM266

C250Ta

C250Ta

C001

C250Ta

C250Ta

C045

C250Ta

C250Ta

D40

C250Ta

C250Ta

UACC62

C250Ta

C250Ta

MM396

C227T/C228T

wt

A07

C227T/C228T

wt

C054

C227T/C228T

wt

C062

C227T/C228T

wt

C057

C241T/C242T

wt

C108

C241T/C242T

wt

D28

C241T/C242T

wt

SKMEL5

C241T/C242T

wt

C250T

wt

C021

b

Homozygous
C021 carried an additional C253T polymorphism.

a

b
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Table 2: Detection of TERT promoter mutations in ctDNA and paired tumor tissue
Tumor Tissue
Plasma ctDNA

+

−

Total

+

8

0

8

−

7

7

14

Total

15

7

22

non-small cell lung cancer [35, 36] and colorectal cancer
[17, 20, 37]. In our study, 7 patients with TERT promoter
positive tumors had no detectable TERT promoter mutations
in matched plasma samples. This is similar to the findings
by Lee et al, who detected ctDNA in 53% of patients prior to
treatment initiation [38]. The lack of detectable ctDNA in a
subset of patients may be explained by the pathophysiology
of the tumor or its metastasis, as ctDNA concentration has
been correlated with tumor size [38-40], metastatic spread
or disease burden [25, 38, 41], tumor vascularization [42]
and site of metastasis [20]. A retrospective analysis of PFS
in this group of patients revealed a significant difference
between patients with negative and positive ctDNA
results. This further supports previous findings that low
or undetectable level of ctDNA is a predictor of long term
treatment benefit [18, 23, 25, 26, 38].
Previous studies have reported detection rates
for BRAF V600E mutations in plasma of metastatic
patients at 76 to 84.3% [25, 26] and for BRAF V600K
at 81 to 89% [18, 26]. In other cancers, Bettegowda et
al. [20] identified mutant ctDNA in 75% of patients with
a variety of cancers including ovarian, breast, bladder,
gastroesophageal and colorectal cancers. Considering our
detection rates of TERT promoter mutations in ctDNA
are lower (53%) than these reports, it would be necessary

for this investigation to be conducted in a larger cohort
controlling for tumor burden, metastatic sites and mutation
variety. Nevertheless, our TERT promoter mutation assay
allowed ctDNA detection in 11 of 38 BRAF wild-type
tumors. Thus, our assay may facilitate ctDNA monitoring
on BRAF wild-type cases, most of which will receive
immunotherapy as a first line of treatment.
Nagore and colleagues [5] have shown that melanoma
patients harboring these specific TERT promoter mutations,
in combination with BRAF/NRAS mutations within their
tumor tissue, have a significantly shorter disease free
survival than patients without this combination. In fact,
Li et al., have shown that TERT promoter mutations are key
downstream targets of the RAS-ERK pathway for malignant
progression of BRAF mutant melanomas [43]. Furthermore,
Akincilar et al. [44] have shown that TERT transcription is
driven by mediation of long-range chromatin interaction and
enrichment of active histone marks through the recruitment
of GABPA to mutant TERT promoters, specifically C228T
and C250T. These authors have consequently suggested that
inhibitors could be designed to hinder TERT transcription in
cancer cells with these mutations. As such, routine genetic
testing of melanoma patients for TERT promoter mutations
in addition to mutant BRAF and NRAS would be clinically
beneficial.

Figure 4: Detection of TERT promoter mutations in plasma. (A) Kaplan-Meier plots of PFS probabilities of patients with

detectable (n=8) and undetectable (n=7) ctDNA levels at baseline. Cox regression p-value, Hazard ratio (HR) and confidence interval
(CI) are indicated. (B) Copies of mutant DNA per mL of plasma were significantly higher in metastatic melanoma patients (MM) (N=56)
compared to healthy controls (Ctrls) (N=56). P=0.006, Mann-Whitney U-test.
www.impactjournals.com/oncotarget
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DNA extraction from FFPE tissue

TERT promoter mutations have been identified
in numerous other cancers such as thyroid, bladder,
hepatocellular cancer and malignant glioblastoma [6-8].
Consequently, the assay described here may allow ctDNA
monitoring in multiple other malignancies. However, the
assay would require validation for each of these cancers.
In conclusion, we report on the development of
a ddPCR assay for the detection of two common TERT
promoter mutations in cell lines, tumor tissue and
ctDNA. Our results suggest that the TERT ddPCR assay
could prove useful as a companion diagnostic to predict
treatment benefit and to monitor response in melanoma
patients and could be extended to other malignancies.

Following review and macrodissection by an
experienced pathologist, genomic DNA (gDNA) was
extracted from 10 x 5μm unstained sections of FFPE
tissue using the QIAamp DNA mini kit (Qiagen) as per
the manufacturer’s instructions. Only FFPE tissues stored
at room temperature, for less than 7 years were used. The
DNA concentration and purity was determined using
the NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE) and Qubit 2.0 Fluorometer
(Life Technologies, USA) instruments.

PCR

MATERIALS AND METHODS

The following primers were used to amplify a
163bp product incorporating both hotspot mutations
(C228T and C250T) in the TERT promoter region: 5’AGCGCTGCCTGAAACTCG -3’ (forward) and 5’CCTGCCCCTTCACCTTCCAG -3’ (reverse). Primers
were synthesized by GeneWorks (Thebarton, SA,
Australia). For optimization of the PCR amplification of
TERT promoter mutations, we first performed end point
PCRs containing, 1 x ddPCR supermix (Bio-Rad), 900
nM of each primer and 50 ng of template gDNA, with
and without 1 x Q solution (Qiagen). Amplifications were
performed using the following cycling conditions: 1 cycle
of 95°C for 15 minutes, 40 cycles of 95°C for 30 seconds
and a range of temperatures from 55°C to 65°C for 30
seconds, followed by 68°C for 30 seconds and 1 cycle
of 68°C for 10 minutes. PCR products of 163bp were
detected by gel electrophoresis on a 1% agarose gel in
Tris-acetate-EDTA (TAE) buffer containing SYBR® Safe
DNA Gel Stain (Life Technologies).

Ethics
This study was approved by the Human Ethics
Committees at Edith Cowan University (No. 11543) and
Sir Charles Gairdner Hospital (No.2013-246).

Genomic DNA extraction
Genomic DNA (gDNA) with known TERT promoter
mutations was obtained from melanoma cell lines 1205Lu
(Wistar Institute) and UACC62 (National Cancer Institute)
to be used as positive controls. In addition, gDNA was
extracted from 39 melanoma cell lines from the QIMR
Berghofer Medical Research Institute [45]. Wild-type
gDNA was obtained from the white blood cell pellets
collected from 4 mL whole blood from one healthy
control. DNA was isolated using the QIAamp DNA
Mini Kit (Qiagen, Australia) as per the manufacturer’s
instructions. gDNA was eluted in AE buffer (Qiagen) and
stored at 4°C until further processing.

Droplet digital PCR
A probe was designed to detect both C228T and
C250T mutation as both mutations result in the same
sequencing string (Figure 1). Due to the short size of
the probe, Locked Nucleic Acid (LNA) bases were
introduced on the bases indicated with a “+” (TERT
Mut:/56-FAM/CCC+C+T+T+CCGG/3IABkFQ/).
A second probe was designed to recognize the C228
loci, also containing LNA bases, (TERT WT, /5HEX/
CCCC+C+T+CCGG/3IABkFQ/). Probes were custom
synthesized by Integrated DNA Technologies (IDT).
Amplifications were performed in a 20 μL reaction
containing 1 x ddPCR Supermix for Probes (No dUTP,
Bio-Rad), 1x Q solution (Qiagen), 250 nM of each probe
and 900 nM of each primer plus template.
Droplets were generated using the Automatic
Droplet generator QX200 AutoDG (Bio-Rad).
Amplifications were performed using the following
cycling conditions: 1 cycle of 95°C (2.5C/s ramp) for

Plasma sample preparation
Blood samples were collected from American
Joint Committee on Cancer (AJCC) stage IV melanoma
patients, prior to initiation of any systemic therapy, into
EDTA vacutainer tubes and stored at 4°C. Plasma was
separated within 24 hours by centrifugation at 1600 g for
10 minutes, followed by a second centrifugation at 2000 g
for 10 minutes, then stored at -80°C until extraction.

DNA extraction from plasma
cfDNA was isolated from 5 mL of plasma from
healthy donors and AJCC stage IV metastatic melanoma
patients using the QIAamp Circulating Nucleic Acid Kit
(Qiagen) as per the manufacturer’s instructions. cfDNA
was eluted in 40 μl AVE buffer (Qiagen) and stored at
-80°C until ctDNA quantification.

www.impactjournals.com/oncotarget
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10 minutes, 40 cycles of 94°C (2.5C/s ramp) for 30
seconds and 57°C for 1 minute, followed by 1 cycle of
98°C (2.5C/s ramp) for 10 minutes. Annealing/extension
temperature was optimized using temperature gradients
from 52°C to 65°C. The sample was held at 4°C until
further processing. Droplets were analyzed through a
QX200 droplet reader (Bio-Rad). QuantaSoft analysis
software (Bio-Rad) was used to acquire and analyze data.
To evaluate the LOD of our TERT ddPCR assay,
gDNA from cell lines 1205Lu (C228T) or UACC62
(C250T) were serially diluted into normal human DNA
obtained from white blood cells of healthy controls to
achieve from 100% to 0% mutant alleles. Each dilution
was tested in a series of eight repetitions all completed in
one run.
Cell lines with known C228T and C250T TERT
promoter mutations, as well as cell lines wild-type for both
mutations (as determined by Sanger sequencing) were
used to validate the assay. The reaction mix was prepared
as above using 50 ng of gDNA as template.
For plasma ctDNA analysis, 5 μL of cfDNA
(maximum template volume possible) was added per
reaction irrespective of the cfDNA concentration. Each
run included a non-template control, gDNA from a healthy
control and gDNA from the cell lines containing the TERT
mutations: 1205Lu (C228T) and UACC62 (C250T).
Only samples with more than two positive droplets were
considered positive. The number of mutated DNA copies
per 20 μl reaction was extrapolated to calculate copies per
mL using the following equation:
Copies/mL of plasma = C*EV/TV/PV.
PV = Volume of plasma used for cfDNA extraction (ml)
EV = Volume in which cfDNA was eluted (μl)
TV = Volume of cfDNA added to the PCR reaction (μl)
C = copies/20μl (data derived from QuantaSoft).

provided expert advice. MAK, TMM and MM recruited
and clinically assessed patients and provided clinical
information. ALP and NKH supplied material, genetic
data and provided expert advice. MZ and ESG designed
experiments, analyzed data, supervised the study and
wrote the paper.
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